AbbVie Q1 Diluted EPS Plunges 46% to $0.39 Despite 12% Revenue Growth
ABBV is trading near its 52-week low of $176.57 (14% above the low) on light trading volume (0.2× avg).
Summary
AbbVie reported first-quarter 2026 results with revenue rising 12.4% year-over-year to $15 billion, driven by strong performance in Skyrizi and Rinvoq, which grew 29% and 20% respectively. However, diluted earnings per share (EPS) significantly declined by 45.8% to $0.39, reflecting product mix shifts, a 40% drop in Humira sales, and continued pipeline investments. This mixed performance, particularly the substantial decline in profitability, will be a key focus for investors following the company's recent full-year adjusted EPS guidance issued in late April. Traders will be closely watching for further details on margin pressures and the impact of strategic investments on future earnings.
At the time of this announcement, ABBV was trading at $200.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $355.4B. The 52-week trading range was $176.57 to $244.81. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.